GlassScriptPhysician profile
Karen Pham
NPI 1245013309
$2,793.65
in general payments reported to CMS, 2019-2025
28 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $946 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.52 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $350.41 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $297.55 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $271.55 | 2025 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $208.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.69 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $109.82 | 2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $109.05 | 2024 | Voquezna |
| Abbvie INC. | $97.89 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $82.87 | 2024-2025 | |
| Glaxosmithkline, LLC. | $79.45 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $75.38 | 2025 | Spravato |
| Vertex Pharmaceuticals Incorporated | $71.71 | 2024-2025 | |
| Intra-Sana Laboratories | $59.04 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Gilead Sciences, INC. | $50.06 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $47.19 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $46.92 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $30.50 | 2025 | |
| Dexcom, INC. | $27.29 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $26.46 | 2025 | Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $23.50 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.70 | 2025 | Caplyta |
| Electromed, INC. | $21.49 | 2025 | Smartvest |
| Kowa Pharmaceuticals America, INC. | $20.20 | 2025 | Zoryve |
| Aimmune Therapeutics, INC. | $17.44 | 2025 | Zenpep |
| Cranial Technologies, INC | $15.94 | 2025 | Doc Band |
| Lnhc, INC | $14.32 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $6.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.